Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank M Balis

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|May 13, 2010
Pediatric phase I trial design using maximum target inhibition as the primary endpointHolly Meany, Frank M Balis, Alberta Aikin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Pharmacokinetics of intrathecal gemcitabine in nonhuman primatesMerrill J Egorin, Eleanor G Zuhowski, Cynthia M McCully, et al.
Pediatric Blood & Cancer|February 16, 2019
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal functionPeter C Adamson, Gareth J Veal, Richard B Womer, et al.
Cancer|April 1, 2005
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysSen H Zhuang, Manish Agrawal, Maureen Edgerly, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2011
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primatesLeigh Marcus, Robert Murphy, Elizabeth Fox, et al.
Pediatric Blood & Cancer|September 5, 2009
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroHolly J Meany, Dan L Sackett, John M Maris, et al.
Cancer|May 13, 2004
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaBrigitte C Widemann, Frank M Balis, Beate Kempf-Bielack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primatesKathleen Neville, Robert A Parise, Patrick Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, et al.
The Oncologist|July 1, 2008
Characteristics and outcome of pediatric patients enrolled in phase I oncology trialsAerang Kim, Elizabeth Fox, Katherine Warren, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|May 13, 2010
Pediatric phase I trial design using maximum target inhibition as the primary endpointHolly Meany, Frank M Balis, Alberta Aikin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Pharmacokinetics of intrathecal gemcitabine in nonhuman primatesMerrill J Egorin, Eleanor G Zuhowski, Cynthia M McCully, et al.
Pediatric Blood & Cancer|February 16, 2019
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal functionPeter C Adamson, Gareth J Veal, Richard B Womer, et al.
Cancer|April 1, 2005
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysSen H Zhuang, Manish Agrawal, Maureen Edgerly, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2011
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primatesLeigh Marcus, Robert Murphy, Elizabeth Fox, et al.
Pediatric Blood & Cancer|September 5, 2009
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroHolly J Meany, Dan L Sackett, John M Maris, et al.
Cancer|May 13, 2004
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaBrigitte C Widemann, Frank M Balis, Beate Kempf-Bielack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primatesKathleen Neville, Robert A Parise, Patrick Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, et al.
The Oncologist|July 1, 2008
Characteristics and outcome of pediatric patients enrolled in phase I oncology trialsAerang Kim, Elizabeth Fox, Katherine Warren, et al.
Pageof 10